New antibody drug JMT108 enters human trials for advanced cancers
NCT ID NCT07317505
First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 18 times
Summary
This early-phase study tests a new drug called JMT108 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive JMT108 by IV every two weeks and are monitored closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Carolina BioOncology Institute
RECRUITINGHuntersville, North Carolina, 28078, United States
Contact
-
NEXT Dallas
RECRUITINGDallas, Texas, 75039, United States
Contact
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Conditions
Explore the condition pages connected to this study.